Polihexanide
drug drugOn this page
Also known as AkantiorCosmocil cqLavaseptMicrocare mbgPolihexanidaPolihexanide hydrochloridePoly(hexamethylenebiguanide)Polyhexamethylene biguanidePuristaVantocil
Summary
Polihexanide (CHEMBL2106939) is an approved small molecule (ATC D08AC05); indicated across 4 conditions including acanthamoeba keratitis and eye infectious disorder.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- ATC class: D08AC05 (+1 more)
- Indications: 4 conditions
- Clinical trials: 5
- Chemistry: 185.27 Da · C8H19N5
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL2106939 |
| Name | Polihexanide |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | no |
| PubChem CID | 20977 |
| ATC | D08AC05, S01AX24 |
| Molecular formula | C8H19N5 |
| Molecular weight | 185.27 |
| InChIKey | VAZJLPXFVQHDFB-UHFFFAOYSA-N |
SMILES: CCCCCCN=C(N)N=C(N)N
IUPAC name: 1-(diaminomethylidene)-2-hexylguanidine
Also known as: Akantior, Cosmocil cq, Lavasept, Microcare mbg, Polihexanida, Polihexanide, Polihexanide hydrochloride, Poly(hexamethylenebiguanide), Polyhexamethylene biguanide, Purista, Vantocil, POLIHEXANIDE
Patent coverage: 3,751 distinct patent families (8,561 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 5,824 (68%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
2 approved indications. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).
| Indication | Phase | MONDO | EFO |
|---|---|---|---|
| Acanthamoeba keratitis | 4 | MONDO:0005629 | EFO:0007126 |
| eye infectious disorder | 4 | MONDO:0043885 | EFO:1001888 |
2 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.
| Disease (in trials) | Phase | MONDO | EFO |
|---|---|---|---|
| fungal infectious disease | 3 | MONDO:0002041 | MONDO:0002041 |
| pulpitis | 2 | MONDO:0006937 | EFO:1001139 |
Clinical trials
Total trials: 5.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE4 | 2 |
| PHASE3 | 1 |
| PHASE2 | 1 |
| Not specified | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT01153620 | PHASE4 | COMPLETED | The Antiseptic Efficacy and Tolerability of Lavasept® 0.04% on Acute Traumatic Wounds |
| NCT01330706 | PHASE4 | COMPLETED | Efficacy of Intraoperative Surgical Scrubbing in Reducing Bacterial Load After Nail Removal Surgery |
| NCT02394821 | PHASE3 | COMPLETED | Odor Management in Fungating Wounds Comparing Metronidazole and Polihexanide |
| NCT05306431 | PHASE2 | COMPLETED | Comparison of Antimicrobial Action of Sodium Hypochlorite and Polyhexamethylene Biguanide as Root Canal Irrigants |
| NCT02375178 | Not specified | COMPLETED | Antimicrobial Activity of Two Mouthwashes |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Indicated for: Acanthamoeba keratitis, eye infectious disorder
- In clinical trials for: fungal infectious disease, pulpitis